Inari Medical Inc. logo

Inari Medical Inc. (NARI)

Delisted
19 Feb 2025
NASDAQ (NGS) NASDAQ (NGS)
$
79. 97
0
0%
$
2.24B Market Cap
- P/E Ratio
- Div Yield
0 Volume
-0.56 Eps
$ 79.97
Previous Close
Investors:
Day Range
79.97 79.97
Year Range
36.73 79.99
Want to track NARI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

NARI Chart

If You Could Only Hold 3 Investments for Life, Consider These

If You Could Only Hold 3 Investments for Life, Consider These

Warren Buffett, who is known to own “forever stocks,” has famously quipped that if you aren't willing to own a stock for 10 years, you shouldn't own it for even 10 minutes.

Marketbeat | 1 year ago
Reasons to Retain Inari Medical Stock in Your Portfolio for Now

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Zacks | 1 year ago
Are You Looking for a Top Momentum Pick? Why Inari Medical, Inc. (NARI) is a Great Choice

Are You Looking for a Top Momentum Pick? Why Inari Medical, Inc. (NARI) is a Great Choice

Does Inari Medical, Inc. (NARI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago

Inari Medical Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
JM
John Malone Amundi
172,843 $16,122 $16,122 - -

Inari Medical Inc. (NARI) FAQ

What does "Delisted" mean?

Inari Medical Inc. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

No stock splits were recorded prior to delisting.

What was the last known trading price?

The stock last traded at $79.97 on Feb 19, 2025 before being delisted.

Inari Medical Inc. Profile

- Industry
- Sector
Mr. Andrew J. Hykes CEO
NASDAQ (NGS) Exchange
45332Y109 CUSIP
US Country
1,300 Employees
- Last Dividend
- Last Split
22 May 2020 IPO Date

Overview

Inari Medical, Inc. is a pioneer in the development of minimally invasive, catheter-based mechanical thrombectomy devices and accessories, aiming to revolutionize treatment in specific disease states across the United States. Initially known as Inceptus Newco1 Inc., the company rebranded to Inari Medical, Inc. in September 2013, marking a new chapter in its quest to tackle complex vascular conditions with innovative solutions. Since its foundation in 2011, and operating out of its headquarters in Irvine, California, Inari Medical has dedicated itself to serving the needs of interventional radiologists, cardiologists, and vascular surgeons through its groundbreaking products.

Products and Services

  • ClotTriever System

Designed for the effective treatment of deep vein thrombosis and peripheral thrombus, the ClotTriever system stands out for its ability to core, capture, and remove large clots from large vessels. This minimally invasive solution offers a new avenue for treating conditions that would have previously required more invasive surgical interventions.

  • FlowTriever System

This innovative mechanical thrombectomy system revolutionizes the treatment of pulmonary embolism and other complex venous thromboembolism cases through large bore catheter-based aspiration. The FlowTriever system is specifically engineered to remove large clots from the peripheral vasculature, offering a safer and more efficient treatment option.

  • InThrill System

Focusing on the treatment of small vessel thrombosis, the InThrill system introduces a novel approach by combining the latest advancements in catheter-based technologies. It is designed to address the challenges associated with accessing and effectively treating thrombosis in smaller vessels.

  • LimFlow System

Targeting patients who suffer from chronic limb-threatening ischemia and have no suitable endovascular or surgical revascularization options, the LimFlow system presents a groundbreaking alternative. This technology potentially reduces the risk of major amputations by providing a new method for revascularizing affected limbs, transforming the treatment landscape for this debilitating condition.

Contact Information

Address: 6001 Oak Canyon, Irvine, CA, United States, 92618
Phone: 877 923 4747